Price$2.77-0.15 (-4.98%)
01:30 PM07:45 PM
News · 26 weeks27-57%
2025-12-142026-06-07
Mix1290d
- Other7(58%)
- SEC Filings5(42%)
Latest news
25 items- PRNXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic CancersBELTSVILLE, Md., June 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today announced the replay availability for its virtual key opinion leader (KOL) event on SIM0505, held following the Company's ASCO 2026 poster presentation of first reported clinical efficacy data from its Phase 1 dose escalation study (June 1, 2026 press release). SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The virtual KOL Event is accessible here. The event featured: Beryl Manning-Geist
- SECNextCure Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - NextCure, Inc. (0001661059) (Filer)
- PRNextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 202655% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg)Favorable safety and tolerability in heavily pretreated population supports ongoing Phase 1 dose-optimization with emphasis on PROC NextCure to host virtual Key Opinion Leader (KOL) Event June 2, 2026 at 8 AM ET BELTSVILLE, Md., June 01, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere Zaiming) an oncology-focused biopharmaceutical company and a subsid
- SECSEC Form 10-Q filed by NextCure Inc.10-Q - NextCure, Inc. (0001661059) (Filer)
- SECNextCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NextCure, Inc. (0001661059) (Filer)
- PRNextCure Provides Business Update and Reports First Quarter 2026 Financial ResultsSIM0505/CDH6 ADC dose optimization initiated in gynecologic cancersSIM0505 Phase 1 dose escalation study data to be presented at ASCO 2026 LNCB74 Phase 1 dose escalation trial update planned in second half of 2026 BELTSVILLE, Md., May 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today provided a business update and reported first quarter 2026 financial results. "Our SIM0505 program reached critical milestones this quarter, headlined by the U.S. Food and Drug Administration (FDA) granting Fast Track designation for platinum-resistant ovarian cancer (PROC) and
- PRNextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic CancersDose optimization will initially be focused on evaluating SIM0505 in patients with platinum-resistant ovarian cancer (PROC) Phase 1 data readout to be presented at ASCO 2026 BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced initiation of the dose optimization portion of the Phase 1 study of SIM0505, focusing on patients with plati
- SECSEC Form DEFA14A filed by NextCure Inc.DEFA14A - NextCure, Inc. (0001661059) (Filer)
- SECSEC Form DEF 14A filed by NextCure Inc.DEF 14A - NextCure, Inc. (0001661059) (Filer)
- PRNextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026BELTSVILLE, Md., April 21, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced a poster will be presented at ASCO 2026 highlighting Phase 1 data for SIM0505 in the treatment of solid tumors. ASCO 2026 is being held May 29 – June 2 in Chicago, Illinois. SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary
- PRNextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian CancerThe U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ovarian cancer (PROC) Phase 1 data for SIM0505 to be presented at ASCO 2026; dose optimization in ovarian cancer expected to begin in Q2 2026 BELTSVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced that the U.S. Food And Drug Administration (FDA) has granted Fast Track Designation for SIM0505 for the treatment of platinum-resistant ovarian cancer. SIM0505 is an
- PRNextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026BELTSVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company, today announced that an abstract for SIM0505 has been accepted for the American Society for Clinical Oncology (ASCO 2026) meeting being held May 29 – June 2 in Chicago, Illinois. SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The ongoing open-label, Phase 1 s
- SECSEC Form 10-K filed by NextCure Inc.10-K - NextCure, Inc. (0001661059) (Filer)
- SECNextCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NextCure, Inc. (0001661059) (Filer)
- PRNextCure Provides Business Update and Reports Full Year 2025 Financial ResultsData readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 2026LNCB74 Phase 1 dose escalation trial update planned in second half of 2026 BELTSVILLE, Md., March 05, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported full year 2025 financial results. "2026 is on track to be transformational for NextCure, as we set the stage to present clinical dose escalation data from the Phase 1 trial for SIM0505, in deve
- SECAmendment: SEC Form SCHEDULE 13D/A filed by NextCure Inc.SCHEDULE 13D/A - NextCure, Inc. (0001661059) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by NextCure Inc.SCHEDULE 13G/A - NextCure, Inc. (0001661059) (Subject)
- INSIDERSEC Form 4 filed by Sr VP, General Counsel Shaw Kevin G.4 - NextCure, Inc. (0001661059) (Issuer)
- INSIDERSEC Form 4 filed by Sr VP, Dev. & Mfg. Kundu Sourav4 - NextCure, Inc. (0001661059) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Richman Michael4 - NextCure, Inc. (0001661059) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Mayer Timothy4 - NextCure, Inc. (0001661059) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Guha Udayan4 - NextCure, Inc. (0001661059) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Cobourn Steven P.4 - NextCure, Inc. (0001661059) (Issuer)
- SECNextCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - NextCure, Inc. (0001661059) (Filer)
- PRNextCure Provides Business UpdateSIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose cohorts BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today provided updates for its two antibody drug conjugate (ADC) programs and reported a preliminary year-end 2025 cash position. SIM0505 (CDH6 ADC): Phase 1 dose escalation data expected in Q2 2026SIM0505 is a novel ADC directed to cadherin-6 (CDH6 ADC), which is overexpressed in several cancers with limited expression in healthy tissues. SIM0505 features a
NXTC FAQ
7 questionsWhat does NextCure Inc. do?
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; and NC762, an immunomedicine targeting a...Where does NXTC stock trade?
NextCure Inc. (NXTC) is listed on NASDAQ.What sector and industry is NXTC in?
NextCure Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did NextCure Inc. go public?
NextCure Inc. (NXTC) completed its IPO in 2019.What are analysts saying about NXTC?
NextCure Inc. has had 4 recent analyst actions on file. The most recent action was from Ladenburg Thalmann: Buy with a $1800.00 price target on 2025-11-07. Recent price targets range from $1400.00 to $1800.00.What companies are similar to NXTC?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NXTC side-by-side with any of them on Quantisnow.How can I track NXTC on Quantisnow?
Quantisnow aggregates NextCure Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NXTC to receive live email and push alerts on every new disclosure.